Imatinib Completed Phase 2 Trials for T Cell Non-Hodgkin's Lymphoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00684411Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma